CL2014003237A1 - Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones. - Google Patents
Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones.Info
- Publication number
- CL2014003237A1 CL2014003237A1 CL2014003237A CL2014003237A CL2014003237A1 CL 2014003237 A1 CL2014003237 A1 CL 2014003237A1 CL 2014003237 A CL2014003237 A CL 2014003237A CL 2014003237 A CL2014003237 A CL 2014003237A CL 2014003237 A1 CL2014003237 A1 CL 2014003237A1
- Authority
- CL
- Chile
- Prior art keywords
- ligand
- kit
- package
- instructions
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653478P | 2012-05-31 | 2012-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014003237A1 true CL2014003237A1 (es) | 2015-07-10 |
Family
ID=48670784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014003237A CL2014003237A1 (es) | 2012-05-31 | 2014-11-27 | Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones. |
Country Status (29)
Country | Link |
---|---|
US (1) | US9675692B2 (es) |
EP (1) | EP2854849B1 (es) |
JP (1) | JP6144758B2 (es) |
KR (1) | KR20150033615A (es) |
CN (1) | CN104349791A (es) |
AR (1) | AR092325A1 (es) |
AU (1) | AU2013267301B2 (es) |
BR (1) | BR112014028997A2 (es) |
CA (1) | CA2872275C (es) |
CL (1) | CL2014003237A1 (es) |
CO (1) | CO7151478A2 (es) |
DK (1) | DK2854849T3 (es) |
EA (1) | EA029779B1 (es) |
ES (1) | ES2668900T3 (es) |
HK (1) | HK1207305A1 (es) |
IL (1) | IL235468A0 (es) |
LT (1) | LT2854849T (es) |
MA (1) | MA37645B1 (es) |
MX (1) | MX357146B (es) |
NO (1) | NO2887943T3 (es) |
NZ (1) | NZ702288A (es) |
PH (1) | PH12014502429A1 (es) |
PL (1) | PL2854849T3 (es) |
PT (1) | PT2854849T (es) |
SG (1) | SG11201407171XA (es) |
SI (1) | SI2854849T1 (es) |
TW (1) | TWI609696B (es) |
UY (1) | UY34842A (es) |
WO (1) | WO2013181486A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201818814T4 (tr) | 2009-10-16 | 2019-01-21 | Oncomed Pharm Inc | Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı. |
EP3485903B1 (en) | 2011-09-23 | 2022-11-16 | Mereo BioPharma 5, Inc. | Vegf/dll4 binding agents and uses thereof |
CA2966042A1 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
US20180200325A1 (en) * | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
CN109071644B (zh) | 2015-09-23 | 2023-09-19 | 昂考梅德药品有限公司 | 治疗癌症的方法和组合物 |
US20210379186A1 (en) * | 2018-04-16 | 2021-12-09 | Merck Patent Gmbh | Additives for protein formulations to improve thermal stability |
PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
WO2022010988A1 (en) * | 2020-07-08 | 2022-01-13 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ctla-4 antibodies |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
ES2644275T3 (es) | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
EP3578168A1 (en) | 2002-02-14 | 2019-12-11 | Chugai Seiyaku Kabushiki Kaisha | Formulation of antibody-containing solutions comprising a sugar as a stabilizer |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2586459B1 (en) | 2005-03-25 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
US20080311078A1 (en) | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
HUE053612T2 (hu) | 2006-06-16 | 2021-07-28 | Regeneron Pharma | Intravitreális bevitelre alkalmas VEGF-antagonista készítmények |
US20100129354A1 (en) | 2006-10-27 | 2010-05-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
TW201039854A (en) | 2009-03-06 | 2010-11-16 | Genentech Inc | Antibody formulation |
TR201818814T4 (tr) * | 2009-10-16 | 2019-01-21 | Oncomed Pharm Inc | Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı. |
CA2781467C (en) | 2009-11-20 | 2015-10-13 | Biocon Limited | Formulations of antibody |
AU2011223919B2 (en) | 2010-03-02 | 2015-03-19 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
SG189220A1 (en) * | 2010-10-06 | 2013-05-31 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
-
2013
- 2013-05-29 AR ARP130101868A patent/AR092325A1/es unknown
- 2013-05-30 TW TW102119047A patent/TWI609696B/zh not_active IP Right Cessation
- 2013-05-31 JP JP2015515218A patent/JP6144758B2/ja active Active
- 2013-05-31 US US13/906,479 patent/US9675692B2/en active Active
- 2013-05-31 ES ES13730702.1T patent/ES2668900T3/es active Active
- 2013-05-31 KR KR1020147035879A patent/KR20150033615A/ko not_active Application Discontinuation
- 2013-05-31 MX MX2014014363A patent/MX357146B/es active IP Right Grant
- 2013-05-31 CN CN201380028578.1A patent/CN104349791A/zh active Pending
- 2013-05-31 PT PT137307021T patent/PT2854849T/pt unknown
- 2013-05-31 UY UY0001034842A patent/UY34842A/es unknown
- 2013-05-31 WO PCT/US2013/043516 patent/WO2013181486A1/en active Application Filing
- 2013-05-31 CA CA2872275A patent/CA2872275C/en active Active
- 2013-05-31 BR BR112014028997A patent/BR112014028997A2/pt not_active IP Right Cessation
- 2013-05-31 DK DK13730702.1T patent/DK2854849T3/en active
- 2013-05-31 EP EP13730702.1A patent/EP2854849B1/en active Active
- 2013-05-31 SG SG11201407171XA patent/SG11201407171XA/en unknown
- 2013-05-31 NZ NZ702288A patent/NZ702288A/en not_active IP Right Cessation
- 2013-05-31 SI SI201330979T patent/SI2854849T1/en unknown
- 2013-05-31 PL PL13730702T patent/PL2854849T3/pl unknown
- 2013-05-31 EA EA201492186A patent/EA029779B1/ru not_active IP Right Cessation
- 2013-05-31 AU AU2013267301A patent/AU2013267301B2/en active Active
- 2013-05-31 LT LTEP13730702.1T patent/LT2854849T/lt unknown
- 2013-05-31 MA MA37645A patent/MA37645B1/fr unknown
- 2013-08-23 NO NO13831626A patent/NO2887943T3/no unknown
-
2014
- 2014-10-29 PH PH12014502429A patent/PH12014502429A1/en unknown
- 2014-11-03 IL IL235468A patent/IL235468A0/en unknown
- 2014-11-27 CL CL2014003237A patent/CL2014003237A1/es unknown
- 2014-12-23 CO CO14281503A patent/CO7151478A2/es unknown
-
2015
- 2015-08-18 HK HK15108004.0A patent/HK1207305A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014003237A1 (es) | Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones. | |
CL2014001930A1 (es) | Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2). | |
CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
IL243303A (en) | Alpha radiation-emitting complexes and pharmaceuticals containing them | |
CL2014001047A1 (es) | Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas. | |
BR112014029403A2 (pt) | conjugados, anticorpo e formulação farmacêutica | |
FR2998570B1 (fr) | Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes | |
CL2014002954A1 (es) | Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos. | |
BRPI0809667A2 (pt) | Composto, medicamento e composição farmacêutica que o contém e uso do composto | |
CL2014000844A1 (es) | Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada. | |
IT1398930B1 (it) | Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi. | |
HK1199712A1 (en) | 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis 18--67--3--17--4--2117- | |
BR112014020992A2 (pt) | Composto,uso de composto na fabricação de um medicamento e composição farmacêutica | |
FR3000670B1 (fr) | Composition cosmetique apaisante a base d'acide salicylique. | |
IL237345B (en) | Antibody and drug conjugates (adc) that bind to 158p1d7 proteins, preparations containing them and their uses | |
IT1403847B1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
CL2013000098A1 (es) | Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. | |
CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
BR112013003530A2 (pt) | ''produto farmacêutico, kit, uso e preparações'' | |
FR2958157B1 (fr) | Composition cosmetique et pharmaceutique comprenant du n-acetyl-glucosamine-6-phosphate | |
CL2014003148A1 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición. | |
IL240949B (en) | Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes | |
CL2014003525A1 (es) | Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension. | |
CL2013002905A1 (es) | Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares. | |
CL2012003265A1 (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo. |